Key Highlights

  • Axon priced $1.0 billion of 0% convertible senior notes due 2031 on Sept. 16, 2026, with an option for $150 million more.
  • The conversion price of about $652.06 is roughly 47.5% above the Sept. 15 close of $442.08; capped calls cost about $99.9 million.
  • Q2 Revenue rose 35% to $904 million and Axon raised its 2026 growth outlook to 32% to 34%.
  • Axon shares fell roughly 10% on Sept. 15 to close at $442.08, and were down by double digits for the year as of Sept. 22 amid the notes offering and Margin concerns.

Axon Enterprise (NASDAQ:AXON) is raising $1.0 billion by selling convertible notes that pay no interest, giving the maker of TASER devices, body cameras and public-safety software fresh Capital for acquisitions, technology Investment and other general corporate purposes. The company priced the offering of 0% convertible senior notes due Sept. 15, 2031, on Sept. 16, 2026, after announcing it a day earlier.

The appeal of the structure is cheap money. Because the notes carry no coupon, Axon pays no cash interest; instead, investors receive the right to convert into Axon shares at a price well above where the stock was trading. The trade-off for existing shareholders is potential dilution if the stock climbs past the conversion price, which Axon has partly offset by buying capped call options.

The market reaction was negative. Axon's shares closed at $442.08 on Sept. 15, the day the plan was announced, and the stock fell roughly 10% that day, extending a slide that began after second-quarter results in early August.

Breaking Down the $1 Billion Zero-Coupon Deal

According to Axon's Sept. 16 pricing announcement, the notes were sold in a private offering to qualified institutional buyers under Rule 144A. The initial purchasers received an option to buy up to an additional $150 million of notes, which would bring the total to $1.15 billion. The offering was expected to settle on Sept. 18.

The initial conversion rate is 1.5336 shares per $1,000 principal amount, equivalent to about $652.06 per share. That is roughly 47.5% above the $442.08 closing price on Sept. 15. Axon can settle conversions in cash, shares or a combination. The company may redeem the notes on or after Sept. 20, 2029, if its stock trades at or above 130% of the conversion price for a specified period.

Axon estimated net proceeds of about $986.0 million, or about $1.13 billion if the additional notes are purchased in full. It planned to use about $99.9 million to pay for capped call transactions, with a cap price of $1,049.94 per share, 137.5% above the Sept. 15 close. Those hedges are designed to reduce dilution, or offset cash payments, if the stock rises above the conversion price up to the cap. The remaining proceeds are earmarked for general corporate purposes, which may include acquisitions and technology investments.

Second-Quarter Growth Stayed Above 30%

The financing arrives while the Business is still growing quickly. On Aug. 5, Axon reported second-quarter revenue of $904 million, up 35% year over year and its 10th straight quarter of growth above 30%. Annual Recurring Revenue rose 39% to $1.6 billion, net revenue retention reached 126%, and future contracted bookings climbed 41% to $15.1 billion.

Adjusted EBITDA rose more than 40% to $242 million, a 26.8% margin. GAAP Net Income was $29 million, or 36 cents per diluted share, and non-GAAP net income was $155 million, or $1.88 per share, both lower than a year earlier because of a large prior-year tax benefit, the company said.

Axon raised its 2026 revenue growth outlook to 32% to 34% from 30% to 32% and guided to an adjusted EBITDA margin of about 25.5%, with capital expenditures of $160 million to $190 million. It ended the quarter with $685 million in cash and short-term investments.

Even so, the shares fell after the report. Management flagged third-quarter margin headwinds from higher memory costs and the absence of a Tariff refund that had helped the second quarter. Adjusted gross margin of 62.9% was down 40 basis points from a year earlier.

From TASER to Drones: The Businesses Behind the Raise

Axon's Connected Devices segment generated $507 million of second-quarter revenue, up 35%, including $261 million from TASER. Platform Solutions revenue, which covers drones, in-car video and related products, more than doubled to $150 million, helped by counter-drone business Dedrone, which supported World Cup security at US stadiums. Software and Services revenue rose 36% to $398 million, driven by new users and premium offerings such as the AI Era Plan and Axon 911.

That breadth helps explain the "acquisitions and technology investments" language in the offering. Axon has used deals to expand into counter-drone systems and emergency-call software, and a larger cash cushion gives it flexibility to keep doing so.

Competitive Landscape in Public-Safety Tech

Axon's main competitor in body cameras and evidence management is Motorola Solutions (NYSE:MSI), which also dominates emergency-communications software. Other rivals include drone makers, real-time crime-center software vendors and a growing list of AI start-ups. Axon's bundled contracts, which combine hardware, cloud software and services over multiyear terms, are a key defense, as the $15.1 billion bookings Backlog shows. Axon said it expects to fulfill 20% to 25% of that backlog over the next 12 months, with the rest recognized over roughly a decade.

Zero-coupon convertibles have become a common funding tool for fast-growing technology companies whose share prices carry high valuations, because investors accept no interest in exchange for Equity upside. The flip side is that such deals often pressure a stock in the short term, as convertible-arbitrage investors who buy the notes often short the shares to hedge their positions.

Weighing the Risks

Convertible notes add Leverage and potential dilution. A Sept. 22 analysis argued that the stock's slide reflected concern about a thinner cash cushion alongside rising debt, and said the shares were down by double digits for the year. Margin pressure from component costs and a heavier professional-services mix is another risk, as is Axon's dependence on government budgets. The stock's premium valuation also leaves little room for execution missteps.

On the other side, the company raised its growth outlook, retains a large contracted backlog and has locked in five-year funding without a cash coupon.

Third-Quarter Margins and the Bookings Backlog

The next major catalyst is Axon's third-quarter report, which the company has typically released in early November. Investors will look for evidence on the margin headwinds management flagged, cash generation after the offering, and progress on body-camera shipments, drones and AI software. Any Acquisition funded with the new capital, and whether the initial purchasers exercise their option for the additional $150 million of notes, are also worth tracking.